Multimodal treatment in Glioblastomas

Authors

DOI:

https://doi.org/10.5222/sscd.2021.83703

Keywords:

Glioblastoma, TTF, tumor treating fields, viral oncolysis, immune check point inhibitors, CAR-T, mesenchymal stem cells

Abstract

Glioblastomas are the most common primary brain tumors. Despite aggressive resection, radiotherapy and concomitant chemotheraphy overall survival is 14-16 months, and 5 year survivial rate is only 2%. The poor prognosis required development of new treatment modalities. Tumor Treating Fields, molecularly targetted drugs, antiangiogenic molecules, immune checkpoint inhibitors, tumor vaccines, Chimeric Antigen Receptor-T cell, viral theraphy and oncolytic viruse and mesenchymal stem cell vectors are some of the modalities that are currently being developed.

Downloads

Download data is not yet available.

Published

2021-04-30

How to Cite

1.
Çetin E, Kabataş S. Multimodal treatment in Glioblastomas. J Nervous Sys Surgery [Internet]. 2021 Apr. 30 [cited 2024 Jul. 25];7(1):14-25. Available from: https://sscdergisi.org/index.php/sscd/article/view/11

Issue

Section

Review